Viewing Study NCT04642469

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:08 PM
Ignite Modification Date: 2026-02-20 @ 8:15 AM
Study NCT ID: NCT04642469
Status: COMPLETED
Last Update Posted: 2024-06-25
First Post: 2020-11-03
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.
Sponsor: AstraZeneca
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Carcinoma, Non- Small Cell Lung View
Keywords:

Keywords

Keyword Brief Keyword Text View
None NCSLC View
None Double-blind View
None PD-L1 View
None MEDI4736 View
None Durvalumab View
None DFS View
None OS View
None MRD+ View
None Lung cancer View